title: Expert recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD).
abstract: Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobiological disorders in childhood, and is characterized by inappropriate levels of inattention, hyperactivity and/or impulsiveness, with an estimated prevalence of 5.29%. ADHD can have a negative impact upon all areas of the life of the patient. The main clinical guides accept multimodal treatment, involving both pharmacological and psychological measures, as the best management approach in ADHD (psychoeducational, behavioural and academic). Lisdexamfetamine dimesylate (LDX) is a new drug for the treatment of ADHD. A multidiscipline expert document has been developed, compiling the scientific evidence referred to this new molecule. The study also addresses the existing shortcomings in current drug therapy for ADHD and the contributions of LDX to routine clinical practice, in an attempt to help and guide physicians in the use of this new treatment. This document is endorsed by the ADHD and Psychoeducational Development task Group of the Spanish Society of Primary Care Pediatrics (Grupo de TDAH y Desarrollo Psicoeducativo de la Asociación Española de Pediatría de Atención Primaria, AEPap), the Spanish Society of Pediatric Neurology (Sociedad Española de Neurología Pediátrica, SENEP) and the Spanish Society of Out-hospital Pediatrics and Primary Care (Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria, SEPEAP).
authors: Servicio de Psiquiatría y Psicología, Hospital Sant Joan de Déu, Barcelona.
authors: José A
authors: JA
authors: Alda
authors: Unidad de Psiquiatría Infantil y Adolescente, Departamento de Psiquiatría y Psicología Médica, Clínica Universidad de Navarra.
authors: César
authors: C
authors: Soutullo
authors: Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron / CIBERSAM / Universitat Autònoma de Barcelona.
authors: Josep A
authors: JA
authors: Ramos-Quiroga
authors: Servicio de Psiquiatría, Hospital Universitario Infanta Leonor en Madrid. Departamento de Psiquiatría. Universidad Complutense de Madrid.
authors: Javier
authors: J
authors: Quintero
authors: Unitat especialitzada en trastorns del desenvolupament (UETD), Hospital Sant Joan de Déu. Servicio de Psiquiatría Infantil y juvenil, Hospital Universitario Mutua de Terrassa. Barcelona.
authors: Amaia
authors: A
authors: Hervás
authors: Unidad de Salud Mental Infanto-Juvenil, Hospital Clínico Universitario Virgen de la Victoria de Málaga.
authors: Isabel
authors: I
authors: Hernández-Otero
authors: Unidad de Trastornos del Aprendizaje (UTAE), Servicio de Neurología, Hospital Sant Joan de Déu Esplugues de Llobregat, Barcelona.
authors: Anna
authors: A
authors: Sans-Fitó
authors: Servicio Neuropediatría, Hospital Son Llatzer, Baleares. Universidad Islas Baleares.
authors: Esther Cardo-Jalón
authors: EC
authors: Cardo-Jalón
authors: Unidad de Neurología Infantil, Hospital Universitario Quirón de Madrid.
authors: Alberto
authors: A
authors: Fernández-Jaén
authors: Centro de Salud de La Felguera, Asturias.
authors: Maximino
authors: M
authors: Fernández-Pérez
authors: Centro de Salud Barrio del Pilar. D.A. Norte. SERMAS. Madrid.
authors: M Inés
authors: MI
authors: Hidalgo-Vicario
authors: Centre Mèdic Sant Ramon. Unidad Clínica Fundación Adana. Barcelona.
authors: Lefa S
authors: LS
authors: Eddy-Ives
authors: Departamento Médico, Shire Pharmaceuticals Ibérica. Madrid.
authors: Javier
authors: J
authors: Sánchez
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate / Q000627:therapeutic use*; D011355:Prodrugs / Q000627:therapeutic use*
chemical_list: D018765:Dopamine Uptake Inhibitors; D011355:Prodrugs; D000069478:Lisdexamfetamine Dimesylate